Connect with us


DARE-19: No significant decrease in major events; dapagliflozin well tolerated in COVID-19 – Healio

The SGLT2 inhibitor dapagliflozin did not significantly reduce risk for organ failure or death or improve recovery among adults hospitalized with COVID-19 vs. placebo,…



Source: Kosiborod M, et al. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
The DARE-19 trial was funded by AstraZeneca. Kosiborod reports he received grants or advisory board, consultant or speaking fees from Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Coffee cuts liver disease death risk in half, study suggests – Yahoo News Australia
Article feature image
Investigational Alzheimer’s drug reduces molecular markers of the disease – News-Medical.Net